Skip to main content

Drug Interactions between Dutrebis and Trimpex

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

trimethoprim lamiVUDine

Applies to: Trimpex (trimethoprim) and Dutrebis (lamivudine / raltegravir)

In a study with 14 HIV-positive patients, coadministration of trimethoprim/sulfamethoxazole (trimethoprim/sulfamethoxazole DS once a day for 5 days) and lamivudine (300 mg single dose on day 5) resulted in a mean decrease of 35% in lamivudine renal clearance and a mean increase of 43% in lamivudine area under the plasma concentration-time curve. The mechanism of interaction is thought to be competitive inhibition of tubular secretion by trimethoprim. Lamivudine did not affect the pharmacokinetic profile of trimethoprim/sulfamethoxazole. Given the favorable safety profile of lamivudine, this interaction is unlikely to be of clinical significance. However, patients with renal dysfunction should be monitored carefully and the lamivudine dose adjusted if necessary. In addition, it should be noted that the effect of higher dosages of trimethoprim/sulfamethoxazole on lamivudine pharmacokinetics has not been investigated.

References

  1. (2001) "Product Information. Epivir (lamivudine)." Glaxo Wellcome
  2. Moore KHP, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, Hussey EK (1996) "Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole." Clin Pharmacol Ther, 59, p. 550-8
  3. Cerner Multum, Inc. "Australian Product Information."

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer